» Articles » PMID: 36482490

Providing Substance Use Disorder Treatment in Correctional Settings: Knowledge Gaps and Proposed Research Priorities-overview and Commentary

Overview
Publisher Biomed Central
Specialty Psychiatry
Date 2022 Dec 9
PMID 36482490
Authors
Affiliations
Soon will be listed here.
Abstract

This manuscript is the product of the authors' discussions, literature overview, and consultation with experts in the field, and identifies important gaps in the evidence base for substance use disorder (SUD) treatment effectiveness within criminal justice (CJ) settings. Lacking from the extant literature are longitudinal investigations of treatment related outcomes during and after incarceration. Such studies could provide rich contextual data about treatment delivery and effectiveness across the CJ continuum, and would provide important insight into individual characteristics (e.g., motivation, treatment modality preferences, treatment completion rates, etc.) as well as institutional and environmental factors (e.g., appropriate staffing, space limitations for individual treatment sessions, distribution of medications, etc.). We also identified the importance of reproducibility within CJ research, and the unfortunate reality of too many single studies conducted in single (or relatively few) correctional facilities. Some of this has been because the studies designed to produce that evidence are not prioritized for funding, which has continually placed researchers in a position where we cannot make firm conclusions or recommendations based on available evidence. The importance of replicating the foundational studies in this field cannot be overstated. We hope this article spurs other researchers to join in the healthy process of questioning the existing state of the CJ-based SUD treatment research, what should be re-examined, and how we can lay a stronger foundation for the future.

Citing Articles

Estimated Use of Prescription Medications Among Individuals Incarcerated in Jails and State Prisons in the US.

Curran J, Saloner B, Winkelman T, Alexander G JAMA Health Forum. 2023; 4(4):e230482.

PMID: 37058293 PMC: 10105311. DOI: 10.1001/jamahealthforum.2023.0482.

References
1.
McLellan A . Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction. 2002; 97(3):249-52. DOI: 10.1046/j.1360-0443.2002.00127.x. View

2.
Farabee D, Condon T, Hallgren K, McCrady B . A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder. J Subst Abuse Treat. 2020; 117:108076. PMC: 7438599. DOI: 10.1016/j.jsat.2020.108076. View

3.
Miller N, Flaherty J . Effectiveness of coerced addiction treatment (alternative consequences): a review of the clinical research. J Subst Abuse Treat. 2000; 18(1):9-16. DOI: 10.1016/s0740-5472(99)00073-2. View

4.
Blanco C, Volkow N . Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019; 393(10182):1760-1772. DOI: 10.1016/S0140-6736(18)33078-2. View

5.
Ferrer B, Connolly J . Racial Inequities in Drug Arrests: Treatment in Lieu of and After Incarceration. Am J Public Health. 2018; 108(8):968-969. PMC: 6050822. DOI: 10.2105/AJPH.2018.304575. View